# A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses

> **NCT07633288** · PHASE2 · RECRUITING · sponsor: **SynAct Pharma Aps** · enrollment: 96 (estimated)

## Conditions studied

- Respiratory Viral Infection

## Interventions

- **DRUG:** AP1189, 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07633288
- **Lead sponsor:** SynAct Pharma Aps
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07633288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07633288, "A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07633288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*